Johnson & Johnson is poised to be a strong contender for joining the exclusive trillion-dollar club over the next decade. Eli ...

Revenues at Johnson and Johnson are still over double those of Eli Lilly over the last twelve months. Looking at net income, ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Companies such as Pfizer, Moderna, and Johnson & Johnson captured myriad headlines ... weight loss. Enter Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the makers behind blockbuster glucagon ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s ...

Here's a quick recap of what I've seen in the biotech and pharma space so far: Johnson & Johnson stole the show when it ... especially under a likely deal-friendly Trump administration. Eli Lilly said ...

The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα ... including one involving another oncology biotech—that of the Johnson and Johnson acquiring Intracellular Therapies. Pharma and ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

Kenvue isn't growing as quickly as Eli Lilly or Zoetis, but it offers investors a strong starting point for dividend income.